Abstract
Nephrotic syndrome (NS) is associated with an acquired hypercoagulopathy and strong predilection for life-threatening thrombotic complications. Current anticoagulant prophylaxis guidelines are based upon controversial hypoalbuminemia thresholds. Anticoagulant prophylaxis is thus inconsistently implemented due to a lack of high-grade safety and efficacy data. Development of evidence-based clinical parameters that define thrombosis risk may thus refine safe and effective anticoagulant use. Endogenous thrombin potential (ETP) is a recognized measure of hypercoagulopathy and established predictor of both incident and recurrent thrombosis. This study utilized biorepository samples from a prospective longitudinal cohort study to demonstrate that ETP is proportional to NS disease activity, resulting in multivariable models that are significantly correlated with ETP. The relationship with disease activity was confirmed in a separate cohort. These models revealed that ETP is related to disease activity in a manner dependent on remission status and that proteinuria and hypercholesterolemia exert the strongest influence on ETP. In contrast to prior epidemiology studies, which did not include hypercoagulopathy measures, we found that hypoalbuminemia was less predictive of ETP. These findings are consistent with our previously reported animal model observations and are expected to inform the design of clinical trials that will generate high-grade evidence to guide more effective and safer anticoagulant use and thus reduce life-threatening thrombotic events in patients with NS.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT01209000
Funding Statement
This project was supported by grants U54DK083912 (MK), U54DK083912-05S1 and U54DK083912-07S1 (MK and BAK), and K08DK103982 (BAK) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and UL1TR002240 from the National Center for Advancing Translational Sciences (NCATS) for the Michigan Institute for Clinical and Health Research. The Nephrotic Syndrome Study Network Consortium (NEPTUNE), U54DK083912, is a part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN), supported through a collaboration between the Office of Rare Diseases Research (ORDR), NCATS, and NIDDK. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional funding and/or programmatic support for NEPTUNE have been provided by the University of Michigan, the NephCure Foundation, and the Halpin Foundation.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵8 See Addendum for Nephrotic Syndrome Study Network (NEPTUNE) Investigators and Affiliations.
Funding Sources: This project was supported by grants U54DK083912 (MK), U54DK083912-05S1 and U54DK083912-07S1 (MK and BAK), and K08DK103982 (BAK) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and UL1TR002240 from the National Center for Advancing Translational Sciences (NCATS) for the Michigan Institute for Clinical and Health Research. The Nephrotic Syndrome Study Network Consortium (NEPTUNE), U54DK083912, is a part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN), supported through a collaboration between the Office of Rare Diseases Research (ORDR), NCATS, and NIDDK. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional funding and/or programmatic support for NEPTUNE have been provided by the University of Michigan, the NephCure Foundation, and the Halpin Foundation.
Data Availability
Data are available via tranSMART data base according to the NEPTUNE ancillary study policy (see: https://www.rarediseasesnetwork.org/cms/neptune/Healthcare-Professionals/Ancillary).
